Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl Fumarate in Primary Progressive Multiple Sclerosis
NCT02959658Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dimethyl fumarate in primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Neurofilament light chain in the cerebrospinal fluid. Started Dec 2016; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT02959658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959658.